多发性骨髓瘤的新药研发与治疗现状

邓书会 安刚 邱录贵

邓书会, 安刚, 邱录贵. 多发性骨髓瘤的新药研发与治疗现状[J]. 中国肿瘤临床, 2020, 47(22): 1135-1139. doi: 10.3969/j.issn.1000-8179.2020.22.061
引用本文: 邓书会, 安刚, 邱录贵. 多发性骨髓瘤的新药研发与治疗现状[J]. 中国肿瘤临床, 2020, 47(22): 1135-1139. doi: 10.3969/j.issn.1000-8179.2020.22.061
Deng Shuhui, An Gang, Qiu Lugui. Development and application of new drugs and therapies for multiple myeloma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 47(22): 1135-1139. doi: 10.3969/j.issn.1000-8179.2020.22.061
Citation: Deng Shuhui, An Gang, Qiu Lugui. Development and application of new drugs and therapies for multiple myeloma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 47(22): 1135-1139. doi: 10.3969/j.issn.1000-8179.2020.22.061

多发性骨髓瘤的新药研发与治疗现状

doi: 10.3969/j.issn.1000-8179.2020.22.061
基金项目: 

国家自然科学基金重点项目 81630007

国家自然科学基金国际(地区)合作与交流项目 81920108006

详细信息
    作者简介:

    邓书会  专业方向为多发性骨髓瘤及淋巴瘤的诊治。E-mail:dengshuhui@ihcams.ac.cn

    邱录贵  中国医学科学院北京协和医学院二级教授,主任医师,博士研究生导师。现任中国医学科学院血液病医院淋巴肿瘤中心主任,天津市脐带血造血干细胞库主任。兼任国际骨髓瘤工作组专家委员会成员、中国抗癌协会血液肿瘤专业委员会主委、中国临床肿瘤学会淋巴瘤研究联盟副主席、中国医师协会整合血液专业委员会副主任委员、中国医药教育协会血液学专业委员会副主任委员、天津市抗癌协会血液肿瘤专业委员会主任委员、中国医药生物技术协会精准医疗分会常务委员等。担任Blood Advances及《中华血液学杂志》等期刊编委/常务编委。主要研究方向为淋巴肿瘤的分子遗传与发病机制和有效治疗策略,干细胞工程。发表论文450余篇,其中SCI收录120余篇

    通讯作者:

    邱录贵  qiulg@ihcams.ac.cn

Development and application of new drugs and therapies for multiple myeloma

Funds: 

the Key Program of National Natural Science Foundation of China 81630007

the International Cooperation and Exchange of the National Natural Science Foundation of China 81920108006

More Information
  • 摘要: 近20年来,多发性骨髓瘤(multiple myeloma,MM)治疗领域出现了划时代的进步。随着免疫调节剂(immunomodulatory drugs,IMiDs)、蛋白酶体抑制剂(proteasome inhibitors,PIs)的出现和普及,患者的治疗疗效明显提高,生存期显著延长,上述两类药物以及自体造血干细胞移植(autologous stem cell transplantation,ASCT)已成为MM治疗的基石。同时,新的药物仍在不断涌现。如新一代的IMiDs、PIs,抗体类药物及其衍生药物及小分子靶向性治疗药物,还出现了嵌合抗原受体T细胞免疫治疗(chimeric antigen receptor T-cell immunotherapy,CAR-T)等手段。上述治疗在MM中均显示出良好的前景。本文旨在对MM领域新药的研发和应用进行综述。

     

  • [1] Tai YT, Anderson KC. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma[J]. Expert Opin Biol Ther, 2019, 19(11):1143-1156. doi: 10.1080/14712598.2019.1641196
    [2] Ghosh A, Mailankody S, Giralt SA, et al. CAR T cell therapy for multiple myeloma:where are we now and where are we headed[J]? Leuk Lymphoma, 2018, 59(9):2056-2067. doi: 10.1080/10428194.2017.1393668
    [3] Morandi F, Horenstein AL, Costa F, et al. CD38:A target for immunotherapeutic approaches in multiple myeloma[J]. Front Immunol, 2018, 9:2722. doi: 10.3389/fimmu.2018.02722
    [4] Kriegsmann K, Dingeldein M, Cremer M, et al. Cell-based immunotherapy approaches for multiple myeloma[J]. Br J Cancer, 2019, 120(1):38-44. doi: 10.1038/s41416-018-0346-9
    [5] Rosenblatt J, Avigan D. Cellular Immunotherapy for multiple myeloma[J]. Cancer J, 2019, 25(1):38-44. doi: 10.1097/PPO.0000000000000356
    [6] Wu C, Zhang L, Brockman QR, et al. Chimeric antigen receptor T cell therapies for multiple myeloma[J]. J Hematol Oncol, 2019, 12(1):120. doi: 10.1186/s13045-019-0823-5
    [7] Nooka AK, Kaufman JL, Hofmeister CC, et al. Daratumumab in multiple myeloma[J]. Cancer, 2019, 125(14):2364-2382. doi: 10.1002/cncr.32065
    [8] Giuliani N, Malavasi F. Editorial:immunotherapy in multiple myeloma[J]. Front Immunol, 2019, 10:1945. doi: 10.3389/fimmu.2019.01945
    [9] Tamura H, Ishibashi M, Sunakawa M, et al. Immunotherapy for multiple myeloma[J]. Cancers (Basel), 2019, 11(12):91.
    [10] Chim CS, Kumar SK, Orlowski RZ, et al. Management of relapsed and refractory multiple myeloma:novel agents, antibodies, immunotherapies and beyond[J]. Leukemia, 2018, 32(2):252-262. doi: 10.1038/leu.2017.329
    [11] Giuliani N, Accardi F, Marchica V, et al. Novel targets for the treatment of relapsing multiple myeloma[J]. Expert Rev Hematol, 2019, 12(7):481-496. doi: 10.1080/17474086.2019.1624158
    [12] Fouquet G, Bories C, Guidez S, et al. Pomalidomide for multiple myeloma[J]. Expert Rev Hematol, 2014, 7(6):719-731. doi: 10.1586/17474086.2014.966074
    [13] Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003):a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2013, 14(11):1055-1066. doi: 10.1016/S1470-2045(13)70380-2
    [14] Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma[J]. Blood, 2017, 130(8):974-981. doi: 10.1182/blood-2017-05-785246
    [15] Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus Pomalidomide and dexamethasone for multiple myeloma[J]. N Engl J Med, 2018, 379(19):1811-1822. doi: 10.1056/NEJMoa1805762
    [16] Mateos MV, Blacklock H, Schjesvold F, et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183):a randomised, openlabel, phase 3 trial[J]. Lancet Haematol, 2019, 6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3
    [17] Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma[J]. Blood, 2017, 130(10):1189-1197. doi: 10.1182/blood-2017-03-775122
    [18] Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM):a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4
    [19] Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR):a randomised, phase 3, open-label, multicentre study[J]. Lancet Oncol, 2016, 17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7
    [20] Dimopoulos M, Siegel D, White DJ, et al. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure:a subgroup analysis of ENDEAVOR[J]. Blood, 2019, 133(2):147-155. doi: 10.1182/blood-2018-06-860015
    [21] Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib-lenalidomidedexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment[J]. Blood Cancer J, 2017, 7(4):e554. doi: 10.1038/bcj.2017.31
    [22] Stewart AK, Dimopoulos MA, Masszi T, et al. Health-related quality-oflife results from the open-label, randomized, phase Ⅲ ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma[J]. J Clin Oncol, 2016, 34(32):3921-3930. doi: 10.1200/JCO.2016.66.9648
    [23] Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma[J]. J Clin Oncol, 2018, 36(8):728-734. doi: 10.1200/JCO.2017.76.5032
    [24] Facon T, Lee JH, Moreau P, et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma[J]. Blood, 2019, 133(18):1953-1963. doi: 10.1182/blood-2018-09-874396
    [25] Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma[J]. N Engl J Med, 2018, 378(6):518-528. doi: 10.1056/NEJMoa1714678
    [26] Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma[J]. N Engl J Med, 2019, 380(22):2104-2115. doi: 10.1056/NEJMoa1817249
    [27] Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE):a randomised, open-label, phase 3 trial[J]. Lancet, 2020, 395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3
    [28] Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA):a randomised, open-label, phase 3 study[J]. Lancet, 2019, 394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1
    [29] Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma:the GRIFFIN trial[J]. Blood, 2020, 136(8):936-945. doi: 10.1182/blood.2020005288
    [30] Caraccio C, Krishna S, Phillips DJ, et al. Bispecific antibodies for multiple myeloma:a review of targets, drugs, clinical trials, and future directions[J]. Front Immunol, 2020.[Epub ahead of print].
    [31] Giuliani N, Accardi F, Marchica V, et al. Novel targets for the treatment of relapsing multiple myeloma[J]. Expert Rev Hematol, 2019, 12(7):481-496. doi: 10.1080/17474086.2019.1624158
    [32] Panowski SH, Kuo TC, Zhang Y, et al. Preclinical efficacy and safety comparison of CD3 bispecific and ADC modalities targeting BCMA for the treatment of multiple myeloma[J]. Mol Cancer Ther, 2019, 18(11):2008-2020. doi: 10.1158/1535-7163.MCT-19-0007
    [33] Zuch DZC, Fajardo F, Zhong W, et al. Targeting multiple myeloma with AMG 424, a novel anti-CD38/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release[J]. Clin Cancer Res, 2019, 25(13):3921-3933. doi: 10.1158/1078-0432.CCR-18-2752
    [34] Bruins W, Zweegman S, Mutis T, et al. Targeted therapy with immunoconjugates for multiple myeloma[J]. Front Immunol, 2020.[Epub ahead of print].
    [35] Trudel S, Lendvai N, Popat R, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159):a dose escalation and expansion phase 1 trial[J]. Lancet Oncol, 2018, 19(12):1641-1653. doi: 10.1016/S1470-2045(18)30576-X
    [36] Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma[J]. Blood, 2017, 130(24):2594-2602. doi: 10.1182/blood-2017-06-793869
    [37] Jhaveri KD, Wanchoo R. Selinexor for refractory multiple myeloma[J]. N Engl J Med, 2019, 381(20):1977. doi: 10.1056/NEJMc1912625
    [38] Stirrups R. Selinexor-dexamethasone for refractory multiple myeloma[J]. Lancet Oncol, 2019, 20(10):e560. doi: 10.1016/S1470-2045(19)30566-2
    [39] Basali D, Chakraborty R, Rybicki L, et al. Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma[J]. Br J Haematol, 2020, 189(6):1136-1140. doi: 10.1111/bjh.16454
    [40] Vaxman I, Sidiqi MH, Gertz M. Venetoclax for the treatment of multiple myeloma[J]. Expert Rev Hematol, 2018, 11(12):915-920. doi: 10.1080/17474086.2018.1548931
  • 加载中
计量
  • 文章访问数:  1418
  • HTML全文浏览量:  527
  • PDF下载量:  462
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-08-24
  • 刊出日期:  2020-12-26

目录

    /

    返回文章
    返回